Robert Hoehn, MD
Psychiatry · Memphis, TNNPI 1396751954
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 49.7% of the total. Reporting peaked in 2023 at $8,297 and has fallen 99.4% since, to $52 in 2025. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $50.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$6K
- Corium, LLC$3K
- Sunovion Pharmaceuticals Inc.$763
- Teva Pharmaceuticals USA, Inc.$468
- AbbVie$451
- Shire North American Group Inc$415
- plus $1K from 13 others
What the payments were for
- Consulting fees$3603%
- Speaking & faculty fees$6,30555%
- Travel & lodging$9398%
- Food & beverage$3,65432%
- Education$2642%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 6 | $5,722 |
| Corium, LLC | 29 | $2,582 |
| Sunovion Pharmaceuticals Inc. | 39 | $763 |
| Teva Pharmaceuticals USA, Inc. | 17 | $468 |
| AbbVie(2 entities) | 31 | $451 |
| Shire North American Group Inc | 37 | $415 |
| Otsuka America Pharmaceutical, Inc. | 14 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $158 |
| Neos Therapeutics, LP | 9 | $116 |
| Johnson & Johnson | 7 | $110 |
| Lundbeck LLC | 7 | $105 |
| Ironshore Pharmaceuticals Inc. | 4 | $95 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $89 |
| Tris Pharma Inc | 6 | $83 |
| Alfasigma USA, Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Alkermes, Inc. | 2 | $33 |
| Adlon Therapeutics L.p. | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,522 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 26 | $125,392 |
| VraylarCariprazine Hcl | 15 | $20,849 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $8,447 |
| Lisdexamfetamine Dimesylate | 14 | $3,986 |
| Bupropion XlBupropion Hcl | 141 | $3,524 |
| Duloxetine Hcl | 127 | $3,055 |
| Aripiprazole | 58 | $2,978 |
| Lurasidone Hcl | 30 | $2,970 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 66 | $2,136 |
| Alprazolam | 248 | $1,800 |
| Ziprasidone Hcl | 42 | $1,791 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 81 | $1,779 |
| Dexlansoprazole DrDexlansoprazole | 11 | $1,300 |
| Clozapine | 44 | $1,286 |
| Lamotrigine | 133 | $1,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $468 | $125,39226 claims |
| AbbVieVraylar | $451 | $20,84915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $158 | $8,44720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Memphis
- Daniel BoydMemphis$69K
- Melissa ShelbyMemphis$14K
- Kenny TerryMemphis$14K
- Anita VarmaMemphis$11K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.